Mumbai, June 21, 2017: Pharma Major,Cadila Healthcare Ltd (Zydus Cadila) today said it has received final approval from the USFDA to market Diflunisal tablets in the strength of 500 mg.
It is a non-steroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh, company said in a filing with BSE.
United News of India
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…